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We tested the truncated 7-37 glucagon-like peptide 1 (TGLP-I), a naturally occurring porcine intestinal peptide, and 
other members of the glucagon family, including pancreatic glucagon (G-29), GLP-1 and GLP-2 for their ability to acti- 
vate the CAMP generating system in rat gastric glands and HGT-I human gastric cancer cells. In rat fundic glands, 
TGLP-1 was about 100 times more potent (EC,, =2.8 x lo+ M) than GLP-1 of G-29, and 10 times more potent than 
G-29 in the HGT-1 cell line. Our results support the notion that TGLP-1 plays a direct role in the regulation of acid 
secretion in rat and human gastric mucosa. 
Enteroglucagon; Proglucagon 78-107; cyclic AMP; (Gastric mucosa, Fundic gland) 
1. INTRODUCTION 
The mammalian glucagon precursor is a 180 
amino acid peptide [ 1,2]. Besides pancreatic 
glucagon (G-29), glicentin (G-69) and oxyn- 
tomodulin (G-37), it contains two glucagon-like se- 
quences, GLP-1 and GLP-2, which share 50% 
homology with G-29. A truncated form of GLP-1, 
lacking the N-terminal 6-amino acid sequence, has 
been isolated from the porcine intestinal mucosa 
[3]. This peptide (TGLP-1) is strongly in- 
sulinotropic [3,4], as opposed to GLP-1, and 
specific receptors for TGLP-1 have recently been 
demonstrated on rat insulinoma cells [5]. In man, 
G-29 is a potent inhibitor of meal- and 
pentagastrin-induced gastric acid secretion [6] and 
stimulates mucus secretion [7]. GLP-1 and 
TGLP-1 both inhibit pentagastrin-induced gastric 
acid secretion in man (81. Consistent with these 
physiological data, G-29 has been shown to ac- 
tivate membrane receptors in rat gastric glands [9] 
and in the human gastric cancer cell line HGT-1 
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[lo]. We therefore studied the effects of G-29, 
GLP-1, TGLP-1 and GLP-2 on the receptor- 
CAMP systems previously evidenced in these two 
models. 
2. MATERIALS AND METHODS 
2.1. Peptides 
TGLP-1, GLP-1, GLP-2 and oxyntomodulin were from 
Peninsula Europe (St. Helens, Merseyside, England). 
Crystalline, pure porcine pancreatic glucagon (G-29) was from 
Novo Research Institute (lot 42306, Bagsvaerd, Denmark). Syn- 
thetic porcine secretin was prepared by Professor E. Wtinsch 
(Max-Planck-Institut fur Peptidchemie, Martinsried, FRG). 
2.2. Tissues 
Adult male Wistar rats (200-250 g) were from our own col- 
ony. Mucosal glands were isolated from the rat fundus and an- 
trum, using EDTA as chelator of divalent cations [ll]. The 
HGT-1 cell line was routinely cultured, as described [12]. 
2.3. CAMP assay 
In a standard CAMP assay, 15081 from the HGT-1 cell 
suspension (l-2 x lo6 cells/ml) or from the rat gastric gland 
preparation (So-150 pg cell protein/ml) was preincubated at 
20°C for 10 min in 250 ~1 KRP buffer containing 1% bovine 
serum albumin (BSA, fraction V) and IBMX as a CAMP 
phosphodiesterase inhibitor [ 11,131. Cyclic AMP was deter- 
mined by our radioimmunoassay method [14]. 
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2.4. Calculations 
The apparent EC_W was the concentration required to pro- 
duce 50% of the maximal stimulation produced by peptides. 
The significance of the differences observed was assessed using 
Student’s t-test. 
3. RESULTS 
As shown in fig.1, TGLP-1 (10-‘“-10-8 M) in- 
creased CAMP production in rat fundic glands 
80-fold with a potency ECso = 2.8 +- 0.7 x 10e9 M 
(n = 6). The glucagon-related peptides GLP-1 and 
G-29 produced similar and parallel dose-response 
curves at a much lower potency: EC50 = 3.4 f 
1.5 x 10m7 M and 2.3 + 0.4 x 10m7 M, respectively 
(n = 6). In contrast, GLP-2 at concentrations as 
high as 4 x 1O-7 M was ineffective in increasing 
basal CAMP levels (3.5 f 0.8 pmol cAMP/mg pro- 
tein, n = 6). We verified that the kinetics of CAMP 
generation induced by either 10M7 M G-29 or 
lo-* M TGLP-1 were similar in rat gastric glands 
(not shown). The three peptides also increased 
CAMP generation in rat antral glands, from 4.0 f 
0.4 to 97 f 10 pmol cAMP/mg protein in the 
presence of 10e7 M TGLP-I (20-fold increase), to 
58 f 10 and 59 f 14 pmol cAMP/mg protein in 
the presence of 10m7 M G-29 and GLP-1, respec- 
tively (n = 3-5 experiments). At maximally effec- 
tive doses, secretin and TGLP-1 produced additive 
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Fig. 1. Effects of the glucagon-like peptides, TGLP-I (e), G-29 
(0), GLP-1 (A) and GLP-2 (A), on CAMP generation in rat 
fundic glands. Cyclic AMP was determined after 1 h incubation 
at 2O”C, in the presence of 0.5 mM IBMX [9]. The results are 
from one experiment, typical of 5 others. Data are means of 
Fig.2. Effects of TGLP-1, G-29, oxyntomodulin and secretin 
alone (0) or in combination with TGLP-1 (8) on CAMP 
generation in rat fundic glands. The peptides were tested at the 
following concentrations: 10m8 M TGLP-1, 1Om6 M G-29, 
10d7 M oxyntomodulin (OX) or lo-’ M secretin (SEC). Values 
shown are the means -t SE of 6 experiments. Each 
duplicate determinations of CAMP production. determination was performed in duplicate. 
stimulations in rat fundic glands (fig.2). In con- 
trast, combinations of G-29 or oxyntomodulin 
with TGLP-1 did not elevate significantly the 
CAMP values measured in the presence of TGLP-1 
alone. 
In HGT-1 human gastric cancer cells, TGLP-1 
increased basal CAMP levels 3.7-fold, from 4.3 -t 
0.6 to 16 + 2.3 pmol/106 cells, with EC50 = 1.8 x 
low9 M (fig.3). Pancreatic glucagon was much less 
potent (EC50 = 1.6 x lo-’ M) but more efficient 
than TGLP-1 in the system (7.5-fold increase over 
basal). The intact peptide GLP-1 and GLP-2 were 
ineffective. 
4. DISCUSSION 
We have shown here that TGLP-1 is the most 
potent glucagon-like peptide so far examined in 
stimulating CAMP production in rat fundic glands 
and the HGT-I cell line. These peptides included 
G-29 [9,10], oxyntomodulin [15,16], GLP-1 and 
GLP-2 in the present study. TGLP-I exhibits the 
same potency in the two systems, being 10 times 
more potent than G-29 in HGT-1 cells and 100 
times more potent than intact GLP-1 and G-29 in 
rat fundic glands. According to its high potency in 
these two models, the present data suggest that 
TGLP-1 is the specific ligand for the glucagon-like 
receptor in gastric mucosa. No additive effect was 
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Fig.3. Effects of the glucagon-like peptides, TGLP-1 (a), G-29 
(o), GLP-1 (A) and GLP-2 (A), on CAMP generation in 
HGT-1 cells. Cyclic AMP was determined after 15 min 
incubation at 20°C in the presence of 1 mM IBMX [13]. Values 
shown are the means + SE of 5 experiments. Each 
determination was performed in duplicate. 
found when TGLP-1 was combined with the other 
natural glucagon analogs, G-29 and oxyn- 
tomodulin. Our data are compatible with the 
hypothesis that TGLP-1 acts on the acid-secreting 
parietal cells in rat fundic glands: (i) the actions of 
TGLP-1 and secretin are additive; (ii) somatostatin 
selectively inhibits CAMP generation induced by 
TGLP-1 and histamine [9,17]. Also consistent with 
these results, is the observation that TGLP-1 is a 
potent inhibtor of in vivo pentagastrin-induced 
gastric acid secretion in man [8]. Truncated GLP-1 
might also exert an effect on mucus secretion since 
glucagon-like peptides elevate CAMP generation in 
rat antral glands and stimulate mucus secretion 
from the surface epithelial cells in the fundic part 
of the human stomach [7]. Similar to its effect on 
insulin secretion [3,4], the truncated GLP-1 pep- 
tide showed a higher potency than the intact 
GLP-1 in rat gastric glands. Thus, from the 
cleavage of active peptides by proteolytic enzymes 
(arginine vasopressin, pancreatic glucagon and 
GLP-1) truncated derivatives arise which have 
potent and new biological activities [3,4,18,19]. 
The present data support the notion that 
TGLP-1 plays an important role in acid and mucus 
secretions in gastric mucosa. In this connection, it 
is interesting that glucagon containing A-like cells 
are present in the oxyntic part of the rat stomach 
[9], suggesting a paracrine action of glucagons, 
together with endocrine secretion from the distal 
gut [3,20]. We and other authors have observed 
that both histamine and glucagon-like peptides in- 
crease CAMP levels in rat parietal cells [9,21]. 
Since histamine and glucagons exert an opposite 
effect on acid secretion [6,8,15,21-231, and re- 
garding the central role of CAMP in acid secretion 
[23], it is therefore likely that other intracellular 
messengers are involved in the inhibition of gastric 
acid secretion by TGLP-1. In the liver, pancreatic 
glucagon has been shown to produce its biological 
effects on two different receptor types [24]. At low 
concentrations, the GR-1 receptor stimulates the 
production of inositol phosphates (0.25 x 
10d9 M), at higher concentrations, the GR-2 recep- 
tor activates the adenylate cyclase system (K, = 6.3 
x 10m9 M). Further studies are therefore required 
to delineate the actual contribution of CAMP and 
inositides in the biological actions of the glucagon- 
like peptides on gastric secretion. 
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